Definitive Contract 75A50119C00034

Award Date 9/25/19
Potential Completion Date 5/7/27
Potential Value $28M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Burlingame, CA 94010, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Inflammatix, Inc., a self-certified small disadvantaged business. The contract is for the development of the HOSTDX-Sepsis diagnostic test, a rapid point-of-care test that analyzes the host immune response to detect and classify sepsis. The contract has a firm fixed price of $510,000.00 and a completion date of November 30, 2021....
This contract was awarded by the Defense Advanced Research Projects Agency (DARPA) to Inflammatix, Inc., a small disadvantaged business, for the development of a host-response prognostic tool called HOSTDXTM-COVID SEVERITY. The $453,851.00 contract is for research, development, and testing services related to diagnostic solutions for COVID-19 and other viral pandemics. Inflammatix has received over $29 million in federal contracts and grants from the Department of Health and Human Services to...
This is a $999,923 Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Inflammatix, Inc., a small disadvantaged business in Sunnyvale, California. The contract is for the development of point-of-care diagnostic solutions to monitor the host-pathogen interaction during infection. Inflammatix has been awarded over $29 million in federal contracts and grants from agencies like the Department of Health and Human Services and...
This federal contract award, valued at $749,549.00, was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Immunexpress Inc., a for-profit foreign-owned company. The contract is for the "ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS" and is a definitive, firm-fixed-price contract with a period of performance ending on June 10, 2023. The contract award originated from a Broad...
This is a $599,551.19 firm-fixed-price contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Cytovale Inc., a small disadvantaged business based in San Francisco, California. The contract is for the Solving the Question of Inflammation or Sepsis Hastily - Decision Impact (SQUISH-DI) study, which aims to evaluate the impact of Cytovale's IntelliSep test on clinical decision-making and sepsis risk...
This is a $52,239,640.00 definitive contract awarded to Visby Medical, Inc. by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. The contract is for the delivery of a rapid, accurate, point-of-care disposable influenza and SARS-CoV-2 molecular diagnostic test. This award is not set aside for any particular business classification. The contract has an ultimate completion date of March 31, 2026. The original solicitation was issued...
This is a $468,104.64 firm-fixed-price contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Cytovale Inc., a small disadvantaged business based in San Francisco, California. The contract is for research and development related to the clinical validation of an at-home, deep-learning based sepsis monitoring system. This contract was awarded under ASPR's Biomedical Advanced Research and Development...
This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
<p>This is a $12,606,489.57 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to AD Astra Diagnostics, Inc. for the research and development of a CLIA-waived ubiquitous early sepsis detection and severity assessment system for use in ambulance, pre-hospital, and post-discharge settings. The contract has an ultimate completion date of December 15, 2027 and does not have a set-aside designation.</p>

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $27,992,718.00 definitive contract to Inflammatix, Inc., a self-certified small disadvantaged business organization, for the development of "a full stack of host-response solutions to infectious disease testing to address outpatient and inpatient testing for acute infections and sepsis both during and outside of influenza season." This contract, which has a performance period ending on May 7, 2027, will support Inflammatix's research, development, and testing of diagnostic cartridges and host-response prognostic tools, including the Triverity cartridge for detecting infection severity and a host-response test called HOSTDX-Sepsis. Inflammatix also leverages federal grants from the National Institutes of Health to conduct research on diagnostic tests for conditions such as sepsis, myocardial infarction, and inflammatory bowel disease, using machine learning and meta-analysis approaches. The contract was awarded on September 25, 2019 and does not have a set-aside designation.

Generated 3/22/24, 4:02 PM